137 related articles for article (PubMed ID: 37901283)
1. The implications when offering percutaneous nephrostomy for the management of malignant obstructive uropathy secondary to urological malignancy: can we be more selective?
Osinibi E; Doan H; Mercado-Campero A; Abbaraju J; Masood S; Madaan S
Ther Adv Urol; 2023; 15():17562872231207729. PubMed ID: 37901283
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous nephrostomy in the management of malignant ureteral obstruction secondary to bladder cancer.
Ekici S; Sahin A; Ozen H
J Endourol; 2001 Oct; 15(8):827-9. PubMed ID: 11724123
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous nephrostomy in obstructing pelvic malignancy does not facilitate further oncological treatment.
Folkard SS; Banerjee S; Menzies-Wilson R; Reason J; Psallidas E; Clissold E; Al-Mushatat A; Chaudhri S; Green JSA
Int Urol Nephrol; 2020 Sep; 52(9):1625-1628. PubMed ID: 32319003
[TBL] [Abstract][Full Text] [Related]
4. Risk factors in the prediction of long-term patency of Resonance metallic ureteric stent in malignant ureteric obstruction.
Ho BSH; Chiu PKF; Lam W; Wong JHF; Wong CKW; Lai TCT; Tsang CF; Ng ATL; Chan CK; Ma WK; Ng CF; Tsu JHL
BJUI Compass; 2020 May; 1(2):74-81. PubMed ID: 35474710
[TBL] [Abstract][Full Text] [Related]
5. The role of percutaneous nephrostomy in malignant ureteric obstruction.
Wilson JR; Urwin GH; Stower MJ
Ann R Coll Surg Engl; 2005 Jan; 87(1):21-4. PubMed ID: 15720902
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right?
Misra S; Coker C; Richenberg J
Int Urol Nephrol; 2013 Jun; 45(3):627-32. PubMed ID: 23666587
[TBL] [Abstract][Full Text] [Related]
7. Easy Method for Percutaneous Nephrostomy Placement with Transrectal Ultrasonography Probe.
Çırakoğlu A; Benli E
J Laparoendosc Adv Surg Tech A; 2019 Dec; 29(12):1565-1570. PubMed ID: 31660792
[No Abstract] [Full Text] [Related]
8. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias.
Romero FR; Broglio M; Pires SR; Roca RF; Guibu IA; Perez MD
Int Braz J Urol; 2005; 31(2):117-24. PubMed ID: 15877830
[TBL] [Abstract][Full Text] [Related]
9. Role of Percutaneous Nephrostomy in Bladder Carcinoma with Obstructive Uropathy: A Story Revisited.
Garg G; Bansal N; Singh M; Sankhwar SN
Indian J Palliat Care; 2019; 25(1):53-56. PubMed ID: 30820102
[TBL] [Abstract][Full Text] [Related]
10. Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature.
New F; Deverill S; Somani BK
Cent European J Urol; 2018; 71(4):404-409. PubMed ID: 30680234
[TBL] [Abstract][Full Text] [Related]
11. Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer.
Nariculam J; Murphy DG; Jenner C; Sellars N; Gwyther S; Gordon SG; Swinn MJ
Br J Radiol; 2009 Jul; 82(979):571-6. PubMed ID: 19153185
[TBL] [Abstract][Full Text] [Related]
12. Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit?
Harris MR; Speakman MJ
Prostate Cancer Prostatic Dis; 2006; 9(1):42-4. PubMed ID: 16402089
[TBL] [Abstract][Full Text] [Related]
13. Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model.
Alawneh A; Tuqan W; Innabi A; Al-Nimer Y; Azzouqah O; Rimawi D; Taqash A; Elkhatib M; Klepstad P
J Pain Symptom Manage; 2016 Feb; 51(2):255-61. PubMed ID: 26497918
[TBL] [Abstract][Full Text] [Related]
14. Factors Affecting Survival Outcome After Percutaneous Nephrostomy as Palliative Urinary Diversion in Obstructive Uropathy due to Advance Cervical Cancer Patients.
Noegroho BS; Kurniawan AP; Wijayanti Z; Mustafa A
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1211-1216. PubMed ID: 33906314
[TBL] [Abstract][Full Text] [Related]
15. Palliation of obstructive nephropathy due to malignancy.
Harrington KJ; Pandha HS; Kelly SA; Lambert HE; Jackson JE; Waxman J
Br J Urol; 1995 Jul; 76(1):101-7. PubMed ID: 7544201
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction.
Alma E; Ercil H; Vuruskan E; Altunkol A; Unal U; Gurlen G; Goren V; Gurbuz ZG
Support Care Cancer; 2020 Nov; 28(11):5581-5588. PubMed ID: 32757161
[TBL] [Abstract][Full Text] [Related]
17. The role of percutaneous nephrostomy in malignant urinary tract obstruction.
Watkinson AF; A'Hern RP; Jones A; King DM; Moskovic EC
Clin Radiol; 1993 Jan; 47(1):32-5. PubMed ID: 8428414
[TBL] [Abstract][Full Text] [Related]
18. Comparison complications rate between double-J ureteral stent and percutaneous nephrostomy in obstructive uropathy due to stone disease:A randomized controlled trial.
Al-Hajjaj M; Sabbagh AJ; Al-Hadid I; Anan MT; Nour Kazan M; Alali Aljool A; Al Muhammad Al Husein H; Tallaa M
Ann Med Surg (Lond); 2022 Sep; 81():104474. PubMed ID: 36147143
[TBL] [Abstract][Full Text] [Related]
19. Comparison between Double J (DJ) Ureteral Stenting and Percutaneous Nephrostomy (PCN) in Obstructive Uropathy.
Ahmad I; Saeed Pansota M; Tariq M; Shahzad Saleem M; Ali Tabassum S; Hussain A
Pak J Med Sci; 2013 May; 29(3):725-9. PubMed ID: 24353616
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Related to Percutaneous Nephrostomies (PCN) in Malignancy-Associated Ureteric Obstruction: A Systematic Review of the Literature.
New FJ; Deverill SJ; Somani BK
J Clin Med; 2021 May; 10(11):. PubMed ID: 34072127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
